Accessibility Menu
 
Actavia Life Sciences logo

Actavia Life Sciences

(OTC) RASP

Current Price$0.00
Market Cap$385,900
Since IPO (2016)-100%
5 Year-99%
1 Year-88%
1 Month-95%

Actavia Life Sciences Financials at a Glance

Market Cap

$385,900

Revenue (TTM)

$0.00

Net Income (TTM)

$407.01K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-135.59 (Low)

Price

$0.00

Volume

20,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

RASP News

No articles available.

RASP: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Actavia Life Sciences

Industry

Biotechnology

Employees

1

CEO

Kunwar Shailubhai, PhD, MBA

Headquarters

New York City, NY 10170, US

RASP Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

2%

Return on Assets

-46%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$385.90K

Shares Outstanding

771.81M

Volume

20.00K

Short Interest

0.00%

Avg. Volume

327.869

Financials (TTM)

Gross Profit

$0.00

Operating Income

$4.24M

EBITDA

$380.00K

Operating Cash Flow

$8.52K

Capital Expenditure

$4.00

Free Cash Flow

$8.52K

Cash & ST Invst.

$74.99K

Total Debt

$210.97K

Actavia Life Sciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$385.90K

N/A

Market Cap/Employee

$385.90K

N/A

Employees

1

N/A

Net Income

$95.52K

+97.7%

EBITDA

$70.94K

-1113.4%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Net Cash

$302.57K

-38.7%

Accounts Receivable

$47.22K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$303.96K

+37.9%

Return on Assets

-46.45%

N/A

Return on Invested Capital

2.17%

N/A

Free Cash Flow

$35.79K

-50.6%

Operating Cash Flow

$35.79K

-50.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VIRXViracta Therapeutics, Inc.
$0.01+0.00%
IPIXInnovation Pharmaceuticals Inc.
$0.00+0.00%
WSNAFWesana Health Holdings Inc.
$0.02+0.00%
PDMIParadigm Medical Industries, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
RITMRithm Capital
$8.77-0.03%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
INFYInfosys
$13.12+0.01%

Questions About RASP

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.